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Abstract: It is widely known that cobalt and chromium ions can enhance the production of reactive oxygen species, 
known to be damaging to cells by disturbing their redox status and then generating oxidative stress. The aim of the present 
study was to determine if increased metal ion levels induce a state of oxidative stress in patients with metal-on-metal 
(MM) hip arthroplasty. Results indicated that there was no significant difference in the concentration of oxidative stress 
markers (total antioxidants, peroxides, and nitrated proteins) in the patients with MM bearings compared to patients 
without prostheses. The activity antioxidant enzymes was stable (catalase and glutathione peroxidase) or slightly 
decreased (superoxide dismutase and heme oxygenase-1) over time. This work is the first to determine the biological 
effects of metal ions released from MM hip implants with regards to mid-term systemic oxidative stress and showed that 
the increased levels of Co and Cr ions are not associated with significant oxidative stress damage in the plasma of patients 
with these implants. 
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INTRODUCTION 
  Metal-on-metal (MM) hip prostheses, made of cobalt-
chromium (Co-Cr) alloys, represent an excellent alternative 
to metal-polyethylene bearings in the treatment of 
osteoarthritis of the hip because of their substantially lower 
wear rates [1]. However, the main concern associated with 
such bearings is the presence of circulating ions in the 
organism [2]. These metal alloys undergo corrosion, either 
electrochemically or mechanically, and release metallic 
particles and ions that disperse systemically [3]. Indeed, 
several studies have shown that Co and Cr particles and ions 
can enter the bloodstream and accumulate both in 
surrounding tissues and organs of patients after MM total hip 
arthroplasty (THA) [4-6]. These ions are potentially toxic [7, 
8], may cause metal hypersensitivity [9, 10], and 
chromosomal aberrations [11], and may induce changes in 
the proportions of peripheral blood lymphocytes [12-14]. 
  The mechanism of metal ion toxicity is not completely 
understood but it is known that they can generate reactive 
oxygen species (ROS), such as superoxide ions (O2
-), 
hydrogen peroxide (H2O2), hydroxyl radical (OH
), and 
nitrogen oxide (NO
) through Fenton/ Haber-Weiss 
chemistry [15]. These ROS are known to be involved in 
numerous human diseases, including degenerative lung and 
heart conditions, Alzheimer disease, rheumatoid arthritis, 
and aging [16]. Additionally, ROS are implicated in the 
induction of oxidative stress generating cell and tissue   
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damage. Oxidative stress may result from an increased 
production of oxidants and/or a decrease in antioxidant 
defense. Since the damage that a ROS produces depends on 
its origin and type, the most accurate and clinically relevant 
measurement of oxidative damage is to measure multiple 
products of this damage [17].
 
  In the present study, we hypothesized that metal ions 
released from MM bearings, namely Co and Cr, could 
generate oxidative stress in the plasma of patients with MM 
THA. We first measured the concentration of both Co and Cr 
ions in blood of patients with 28 mm-head MM prostheses. 
We then evaluated the concentrations of total antioxidants 
(TAS), peroxides, and nitrated protein as markers of 
oxidative stress in the plasma of these patients. TAS 
measures the overall antioxidant capacity of serum samples 
while peroxides were used as a marker of lipid peroxidation 
and nitrated proteins (nitrotyrosines) as a marker of damage 
to proteins. Since the induction of oxidative stress is also 
related to the activity of specific antioxidant enzymes, we 
measured in a second step the activity of some of these 
enzymes in the plasma of these patients. We specifically 
looked at classical antioxidant enzymes [18] such as catalase 
(CAT), glutathione peroxidase (GPx), and superoxide 
dismutase (SOD), as well as the non-classical antioxidant 
enzyme heme oxygenase-1 (HO-1) [19]. These enzymes 
were chosen because their expression (CAT, GPX, and 
SOD) is modulated by Co and Cr ions in human MG-63 pre-
osteoblasts  in vitro [20] and are implicated in multiple 
human disease processes [18] and also because the induction 
of HO-1 is a general response to oxidative stress in 
mammalian cells [21]. 222    The Open Orthopaedics Journal, 2010, Volume 4  Tkaczyk et al. 
  In a recent study [22], it has been showed that the levels 
of oxidative stress markers are not elevated in the plasma of 
patients 1 year after the implantation of MM bearings. To the 
best of our knowledge, the present paper is the very first 
study of its kind attempting to further understand the clinical 
significance of elevated metal ion levels by evaluating their 
mid-term effect at the circulating oxidant/antioxidant level. 
MATERIALS AND METHODOLOGY 
Study Groups 
  A total of 127 patients having a 28 mm-head MM 
articulating interface (Metasul, Zimmer, Warsaw, IN, USA) 
were included in the study. No funds were received for this 
study. Exclusion criteria were determined specifically 
attempting to minimize alternate sources of increased metal 
ions in blood. Indeed, the exclusion criteria were bilateral 
hip involvement, infection, any current metal hardware, and 
severe medical disability limiting ambulation. The study was 
approved by our Institutional Review Board. Prior ethics 
committee approval and informed written consent were 
obtained. The patients were separated into 5 groups: 1) the 
control group (pre-operative: Pre-OP) includes 46 patients; 
2) 40 patients were included in the “less than 6 months” 
group; 3) 23 patients were included in the “1-2 years” group; 
4) 28 patients were included in the “3-4 years” group; 5) 36 
patients were included in the “more than 4 years” group. 
Patients before surgery were chosen as control subjects 
because they allow comparing groups of similar age and 
health conditions. The most common diagnosis for surgery 
in all groups was osteoarthritis (71% to 85% of patients) 
while rheumatoid arthritis was the cause for surgery in 0 to 
12 % of the patients (Table 1). 
Table 1.  Diagnosis of Patients in the Different Study Groups 
 
 OA  RA  CDH  AVN 
Pre-OP (Control)  83% 10%  7%  0% 
 6 months  71% 8%  13% 8% 
1-2 years  72% 6%  11% 11% 
3-4 years  85% 0% 7.5%  7.5% 
> 4 years  79% 12%  6%  3% 
OA: Osteoarthritis; RA: Rheumatoid arthritis; CDH: Congenital dislocation of the hip; 
AVN: avascular necrosis. 
 
  The age of patients at the time of blood sampling was 
similar for the 5 groups. The percentage of smokers varied 
from 14% of the patients (less than 6 months group) to 7% in 
the control Pre-OP group (Table 2). The Harris Hip Scores 
(HHS) and the UCLA activity scores were also similar, 
except for the control Pre-OP and the less than 6 months 
groups that had lower results. 
Blood Samples and Ion Concentrations 
  Whole blood samples were collected in Sarstedt 
Monovette tubes equipped with needles for trace metal 
analysis (Sarstedt, Montreal, QC) and kept at -80ºC until 
analysis. Co and Cr ions levels were measured as previously 
described by inductively coupled plasma mass spectrometry 
(ICP-MS, PerkinElmer SCIEX Elan 6100 DRC ICP-MS 
system; PerkinElmer Instruments, Norwalk, CT) at the 
Geochemical Laboratories of McGill University [22]. The 
biological reference standard SeroNorm Trace Elements 
Whole Blood, Level 2 (Sero AS, Billingstad, Norway) was 
analyzed as a quality-control sample. 
Plasma Preparation 
  Whole blood of patients (1.5 ml) was also collected into 
Sarstedt Li-Heparin tubes and centrifuged at 500 x g for 10 
min. Supernatant (plasma) was stored at -80ºC for later 
analysis. Plasma was chosen for this part of the study instead 
of whole blood because the assays for oxidative stress are 
not recommended for whole blood and can lead to erroneous 
data. 
Oxidative Stress Markers 
  Total antioxidant status (TAS) was measured in the 
plasma using the Oxford Biomedical total antioxidant power 
kit (Oxford, MI, USA). This assay is based on the capacity to 
prevent the ABTS (2-2’-Azino-di-[3-ethylbenzthiazoline 
sulphonite]) oxidation by metmyoglobin and has an inter-
assay coefficient of variation (CV) of 3%. 
  Lipid peroxidation was measured as the total peroxide 
concentration in the plasma using the Biomedica OxyStat 
assay (Medicorp, Montreal, QC), which assesses the 
concentration of an orange complex formed by the oxidation 
of Fe
2+ by peroxides contained in samples. The assay has a 
5.1% CV inter-assay precision. 
  Plasma nitrotyrosine levels (nitrated proteins) were 
quantified using the BIOXYTECH
® Nitrotyrosine-EIA assay 
(OxisResearch
™, Portland, OR, USA) that has an 11.2%CV 
inter-assay precision. 
Antioxidant Enzymes 
  The three types of superoxide dismutases (Cu/Zn-, Mn-, 
and Fe-SOD) present in the plasma were assessed by a 
colorimetric assay (Superoxide Dismutase Assay kit, 
Table 2.  Demographic Data and Outcome Measures of Patients in the Different Study Groups 
 
  Age (Range)  Male/Female  Smoker  HHS  UCLA 
Pre-OP  55 ± 9 (39-76 y)  23M/23F  7%  47 ± 14  4.8 ± 2.3 
 6 months  60 ± 10 (42-71 y)  8M/32F  14%  75 ± 16  4.7 ± 1.9 
1-2 years  56 ± 11 (31-72 y)  4M/19F  11%  85 ± 14  6.0 ± 1.3 
years  51 ± 8 (32-64 y)  12M/14F  8%  87 ± 13  6.6 ± 1.6 
> 4 years  52 ± 8 (33-65 y)  21M/15F  8%  90 ± 11  7.1 ± 1.6 Elevated Blood Metal Ion Levels in Patients with Metal-On-Metal Prostheses  The Open Orthopaedics Journal, 2010, Volume 4    223 
Cayman, Ann Arbor, MI, USA). Cayman’s superoxide 
dismutase assay kit utilizes a tetrazolium salt for detection of 
superoxide radicals generated by xanthine oxidase and 
hypoxanthine. One unit of SOD is defined as the amount of 
enzyme needed to exhibit 50% dismutation of the 
superoxide. It has a 3.2%CV inter-assay precision. 
  Catalase (CAT) activity was measured in the plasma of 
patients using the Catalase Assay kit of Cayman, a 
colorimetric test based on the capacity of CAT to produce 
formaldehydes after hydrolyzing H2O2. The inter-assay CV 
is 3.8%. 
  The Glutathione Peroxidase Assay kit of Cayman was 
used to determine the activity of all the glutathione 
peroxidases (GPX) present in patient plasma. This assay 
measures GPX activity indirectly by a coupled reaction with 
glutathione reductase and has a 5.7%CV inter-assay 
precision. 
  The presence of heme oxygenase-1 (HO-1) was assessed 
using the Human HO-1 ELISA kit from Assay Designs (Ann 
Arbor, MI, USA) in which a mouse monoclonal antibody 
specific to human HO-1 is immobilized on wells and 
captured HO-1 present in samples. The sensitivity of the 
assay is 0.78 ng/mL. 
Statistical Analysis 
  TAS, peroxides, CAT, and GPX data were symmetrically 
distributed. Therefore, ANOVA followed by Scheffe’s test 
was used to compare the different study groups. Metal ion, 
nitrotyrosine, SOD, and HO-1 data distributions were 
asymmetric and variability between groups was significant. 
The Kruskall-Wallis test that is a nonparametric equivalent 
of a one-way analysis of variance was used. It is calculated 
as a regular ANOVA, but uses the ranks of the data and is 
therefore resistant to outliers represented by the dots (•) in 
the box-plot visualization of results, in which the box by 
itself represent the middle 50% (25% to 75% percentiles) of 
the data. To facilitate calculations, all null values were 
defined as the half of lowest sensitivity range of the assay. A 
p value < 0.05 was considered as significant. 
RESULTS 
 Fig.  (1) corresponds to the levels of Co and Cr ions in 
blood of patients with 28 mm-head MM prostheses. Results 
showed a significant increase of both Co (Fig. 1A) and Cr 
(Fig. 1B) in the blood of these patients within 6 month after 
their hip replacement surgery. The level of Co increased 
from 1.88 ppb in Pre-OP patients to 2.51 ppb in the less than 
6 months patients, while the level of Cr passed from 0.35 
ppb in Pre-OP patients to 0.72 ppb in the less than 6 months 
patients. The levels of both Co and Cr ions then reached a 
plateau at 1 year and stayed stable thereafter. 
 Figs.  (2-4) show the concentration of oxidative stress 
markers in the plasma of patients with 28 mm-head MM 
prostheses. Results showed that there were no differences 
between the various time groups for TAS with 
concentrations varying from 982 to 1398 mM (Fig. 2), 
peroxides with concentrations varying from 299 to 502 
nmol/ml (Fig. 3), and nitrotyrosines with concentrations 
varying from 115 to 375 nM (Fig. 4), suggesting that the 
increased levels of Co and Cr ions did not induce oxidative 
stress damage in the plasma of these patients. 
 
Fig. (1). Co and Cr ion concentrations in the blood of patients with 
MM THAs. Due to non-parametric distribution, results are 
presented as box plot in which outliers are represented by the dots 
(•) and the box by itself represents the middle 50% of the data.  
 p < 0.05 vs control. 
 Figs.  (5-8) show the activity of antioxidant enzymes in 
the plasma of patients. Results showed that SOD 
significantly decreased by 65.8% in the plasma of patients 1-
2 years after surgery (p = 0.005) (Fig. 5). This decrease was 
transient with a progressive return to control value after 3 
years. The activity of SOD in the more than 4 year group 
was even higher than in the control (p = 0.038), the less than 
6 month group (2.4 times; p = 0.0486), the 1-2 year (7.8 
times; p = 0.006), and the 3-4 year (1.3 times; p = 0.02) 
groups (Fig. 5). These results suggest that Co and Cr ions 
from MM THA may modify SOD activity in the plasma of 
patients with 28 mm-head MM prostheses. Results also 
showed slow, but not significant changes in CAT activity for 
all time intervals (Fig. 6). There were also no statistical 
differences in the activity of GPX (Fig. 7) between the five 
groups. Finally, the level of HO-1 decreased after 
implantation of the prostheses with statistical difference 
observed at 1-2 year (p = 0.03), at 3-4 year (p = 0.005), and 
after 4 years (p = 0.009) comparatively to the control group 
(Fig. 8). In the more than 4 year group, the decrease reached 
30% of the control level. The HO-1 level was also lower in 
the 1-2 year (p = 0.01) and the 3-4 year (p = 0.006) groups 
compared to the less than 6 month group. These decreases in 
HO-1 levels suggest a role for Co and Cr ions in the 
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modulation of circulating HO-1 in patients with 28 mm-head 
MM prostheses. 
 
Fig. (2). Total antioxidant status (TAS) in the plasma of patients 
with MM THAs. Results are expressed as the mean ± standard 
deviation. 
 
Fig. (3). Peroxide concentrations in the plasma of patients with MM 
THAs. Results are expressed as the mean ± standard deviation. 
 
Fig. (4). Nitrotyrosine concentrations in the plasma of patients with 
MM THAs. Due to non-parametric distribution, results are 
presented as box plot in which outliers are represented by the dots 
(•) and the box by itself represents the middle 50% of the data. 
DISCUSSION 
  The present study showed that levels of Co and Cr ions 
increased rapidly after surgery in the blood of patients with 
28 mm-head MM THA. The levels of both Co and Cr ions in 
our study were in the same range as those reported in 
previous studies [23-30] using different prostheses, with 
mean or median Co ion levels varying from 0.7 to 2.2 ppb 
(12 to 38 nmol/L) and mean or median Cr ion levels varying 
from 1.3 to 2.8 ppb (24 to 53 nmol/L). However, due to 
differences in the choice of samples (erythrocyte vs serum vs 
whole blood) and in the methodology (digested samples vs 
diluted samples; ICP-MS vs graphite furnace), it is 
impossible to identify a prosthesis that releases the least 
amount of ions into patient circulation. 
 
Fig. (5). Superoxide dismutases (SODs) activity in the plasma of 
patients with MM THAs. Due to non-parametric distribution, 
results are presented as box plot in which outliers are represented 
by the dots (•) and the box by itself represents the middle of the 
data. p < 0.05 vs control; *p < 0.05 vs  6 months. 
 
Fig. (6). Catalase (CAT) activity in the plasma of patients with MM 
THAs. Results are expressed as the mean ± standard deviation. 
 
Fig. (7). Glutathione peroxidase (GPX) activity in the plasma of 
patients with MM THAs. Results are expressed as the mean ± 
standard deviation. 
  The rapid increase in blood ions found in the first year is 
also comparable to what was observed by other groups [28-
30]. This increase was followed by a plateau by 4 years. This 
suggests that, in vivo, the run-in phase of accelerated wear is 
indeed limited to the first 2 years postoperatively. A steady-
state phase was reached from 6 months after surgery. In the 
present study, the number of patients per group and the fact 
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that the study is not longitudinal (as the groups are formed of 
different patients) did not allow confirmation of this plateau. 
The similarity between previous longitudinal studies [28-30] 
and the present study support the validity of our results even 
if their non-longitudinal aspect may represent a bias in the 
analysis of metal ions. The fact that the male/female ratio is 
not the same in all the study groups represents another 
limitation of the study. However, a previous study showed 
no differences between the levels of metal ions in males and 
females and patients with surface replacements [22] and this 
ratio discrepancy probably have any effect on the general 
trends of the data. Results from the present study have in 
counterpart the advantage of having been obtained with the 
same method of measurement (needles, tubes, solutions, 
standard, and technology (ICP-MS)) up to 10 years post-
operatively. Indeed, when we subdivided the more than 4 
years group, there was no statistical differences in the levels 
of Co and Cr ions between the 5-6 years group (22 patients) 
and the  7 years group (14 patients) (p > 0.8) (results not 
shown). This remains to be confirmed with larger groups of 
patients. 
 
Fig. (8). Heme oxygenase-1 (HO-1) concentrations in the plasma of 
patients with MM THAs. Due to non-parametric distribution, 
results are presented as box plot in which outliers are represented 
by the dots (•) and the box by itself represents the middle 50% of 
the data.  p < 0.05 vs control; *p < 0.05 vs  6 months. 
  The single most significant obstacle preventing a broader 
application of MM hip arthroplasties and resurfacings 
continues to be the concerns regarding elevated metal ion 
levels in the blood, urine, and tissues of patients with these 
bearing surfaces, especially in young patients [2]. An 
elevation of chromosomal aberrations was described in 
peripheral blood lymphocytes within 2 years postoperatively 
in patients with MM implants. However, as mentioned by 
the authors themselves, chromosomal aberrations are not 
necessarily associated with increased cancer incidence [31]. 
Moreover, the same group also showed chromosome 
aberrations in patients with metal-polyethylene implants 
requiring revision [32]. Visuri et al. initially reported a 
relative higher incidence of hematopoietic cancers in patients 
with MM prostheses [33]. In the later study, however, the 
patient population was relatively small and no adjustments 
were made for co-morbidities that increase the patient risk of 
developing neoplasm (such as rheumatoid arthritis, Paget’s 
disease, or bone infarcts). More recently, in a thorough 
evaluation of a larger cohort of patients, Visuri et al. were 
unable to demonstrate a relative increased risk of cancer in 
patients with MM prostheses [34]. Finally, in a meta-analysis 
of 8 epidemiologic studies including over 130,000 patients 
with total hip and knee arthroplasties, no causal link could be 
established between MM hip bearings and cancer [35]. 
Nevertheless, continued surveillance of patients with MM 
bearings is warranted to understand the clinical relevance of 
raised metal ions in these patients. 
  In an ongoing need to assess the potential consequences 
of elevated ion levels, we chose to evaluate oxidative stress 
markers in the plasma of our patient population with MM 
THAs. Metal ions have the potential to induce the production 
of reactive oxygen species (ROS), making them prime 
suspects for disturbing the balance of oxidants/antioxidants 
in circulating cells [15, 36, 37]. This oxidant/antioxidant 
unbalance has been identified in numerous degenerative 
processes including Alzheimer’s disease, macular 
degeneration, rheumatoid arthritis, neoplasm, and aging [16]. 
In the present study, we showed that there were no changes 
in the levels of three oxidative stress markers (TAS, 
nitrotyrosine, and peroxides) and few changes in the activity 
of four antioxidant enzymes in the plasma of patients with 28 
mm-head MM prostheses compared to the control group, 
suggesting that the increased levels of metal ions in patients 
with MM THA had no or little effect on oxidative stress in 
the plasma of these patients. The results also stayed the same 
if we subdivided the more than 4 years group into a 5-6 years 
group and a more than 7 years group as observed for metal 
ions. Our results suggest that the increased levels of metal 
ions were not sufficient to disturb the overall defense 
antioxidant system (as measured by TAS) of patients with 28 
mm-head MM prostheses. Notwithstanding the nonexistence 
of significant mid-term systemic oxidative stress, oxidative 
stress and/or pathologies in peri-prosthetic tissues cannot be 
excluded. 
  Oxidative stress occurs when the balance of formation of 
oxidants exceeds the ability of antioxidant systems to 
remove ROS. Actually, it was shown that Co and Cr could 
modify the expression of CAT and GPX in human MG-63 
pre-osteoblasts [20] and that the lack of SOD in knockout 
mice has dramatic repercussions on phenotypes with 
perinatal or early postnatal mortality [38]. Moreover, these 
enzymes are involved in many pathophysiological processes 
including neurodegeneration, cancer, and aging [18, 39]. In 
this regard, the antioxidant status and the levels of oxidative 
stress markers are altered in patients with osteoarthritis [40, 
41] and rheumatoid arthritis [41, 42] this may affect results 
of the present study. However, patients from all groups have 
similar diagnosis and this has probably a very small impact 
on the results. Results of the present study show that the 
overall capacity of plasmatic antioxidant enzymes to remove 
ROS was not affected by metal ion levels in patients with 28 
mm-head MM prostheses. We observed a transient decrease 
of SOD at 1-2 years postoperatively with a return to control 
values thereafter. The SOD activity we measured in the 
plasma corresponded to SOD3 (extracellular SOD) that is 
present in low concentration compared to cellular SODs. 
Furthermore, SOD3 present in extracellular spaces of tissues 
accounts for 90-99% of the SOD3 present in the body. This 
low concentration of SOD3 circulating in plasma may make 
it more sensitive to minor changes of oxidative status [43]. 
This may explain the variation of SOD activity observed in 
plasma of patients with 28 mm-head MM prostheses whereas 
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the other antioxidant enzymes were not affected in the same 
conditions. Our results are in agreement with a previous 
study in COS7 cells where cobalt chloride led to a decrease 
in the resistance to oxidative damage by down-regulating the 
expression of SOD3 [44]. 
  Interestingly, it was shown that Co
2+  decreased the 
expression of CAT in a time- and dose-dependent manner, 
while Cr
3+ increased its expression
 in osteoblast-like cells in 
vitro [20]. In the present study, we observed a tendency to 
decreased CAT activity in the plasma of patients with MM 
prostheses. This suggests that metal ions from MM 
prostheses, especially Co
2+, may affect plasma CAT activity 
at long-term. The activity of CAT in long-term follow-up 
remains then to be investigated. 
  HO-1 is also known to be implicated in many human 
diseases such as Alzheimer and inflammatory diseases [21]. 
Previous findings showed that Cr(VI) induced the expression 
of HO-1 in human dermal fibroblasts [45]. This suggests that 
Cr ions were not implicated in the progressive decrease of 
HO-1 we observed in patients with MM THA up to 4 years 
post-operatively. However, HO-1 increased at longer term   
(> 4 years), suggesting that the effect might be reversible. A 
down-regulation of HO-1 was shown in vivo in patients with 
hepatitis C, while other antioxidant enzymes, such as CAT 
and SOD, were not affected [46]. This suggests that 
parameters other than the presence of metal ions might be 
responsible for the decreased levels we observed in patients 
with MM prostheses. 
CONCLUSION 
  This work is the first to determine the biological effects 
of metal ions released from MM hip implants with regards to 
mid-term systemic oxidative stress and showed that the 
increased levels of Co and Cr ions were not associated with 
significant oxidative stress damage in the plasma of patients 
with these implants. 
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